Barash I
J Mammary Gland Biol Neoplasia. 2025; 30(1):3.
PMID: 40048007
PMC: 11885404.
DOI: 10.1007/s10911-025-09578-4.
Blanco R, Munoz J
Biology (Basel). 2025; 14(2).
PMID: 40001942
PMC: 11851556.
DOI: 10.3390/biology14020174.
Fadebi O, Miya T, Khanyile R, Dlamini Z, Marima R
Noncoding RNA. 2025; 11(1).
PMID: 39997609
PMC: 11857994.
DOI: 10.3390/ncrna11010009.
Radhi J, El-Hagrasy A, Almosawi S, Alhashel A, Butler A
Cancers (Basel). 2025; 17(3).
PMID: 39941709
PMC: 11815763.
DOI: 10.3390/cancers17030337.
Cejalvo Andujar J, Ayala de la Pena F, Margeli Vila M, Pascual J, Tolosa P, Pages C
Cancer Drug Resist. 2025; 8:5.
PMID: 39935426
PMC: 11810462.
DOI: 10.20517/cdr.2024.169.
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors.
Murray C, Kornepati A, Ontiveros C, Liao Y, de la Pena Avalos B, Rogers C
Mol Cancer. 2024; 23(1):242.
PMID: 39478560
PMC: 11523829.
DOI: 10.1186/s12943-024-02147-z.
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors.
Cadzow L, Brenneman J, Tobin E, Sullivan P, Nayak S, Ali J
Cancer Res. 2024; 84(20):3419-3434.
PMID: 39402989
PMC: 11474170.
DOI: 10.1158/0008-5472.CAN-24-0293.
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer.
Xie Y, Xiao D, Li D, Peng M, Peng W, Duan H
Front Oncol. 2024; 14:1441222.
PMID: 39156700
PMC: 11327142.
DOI: 10.3389/fonc.2024.1441222.
Reversion of pathogenic L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer.
Jo S, Lee J, Won J, Park J, Kweon T, Jo S
iScience. 2024; 27(8):110469.
PMID: 39156639
PMC: 11326956.
DOI: 10.1016/j.isci.2024.110469.
Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers.
Matuszczak M, Kiljanczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P
Antioxidants (Basel). 2024; 13(7).
PMID: 39061909
PMC: 11273827.
DOI: 10.3390/antiox13070841.
A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity.
Sellars E, Savguira M, Wu J, Cancelliere S, Jen M, Krishnan R
iScience. 2024; 27(7):110180.
PMID: 38993666
PMC: 11238136.
DOI: 10.1016/j.isci.2024.110180.
The molecular evolution of cancer associated genes in mammals.
MacDonald N, Raven N, Diep W, Evans S, Pannipitiya S, Bramwell G
Sci Rep. 2024; 14(1):11650.
PMID: 38773187
PMC: 11109183.
DOI: 10.1038/s41598-024-62425-0.
UFL1 triggers replication fork degradation by MRE11 in BRCA1/2-deficient cells.
Tian T, Chen J, Zhao H, Li Y, Xia F, Huang J
Nat Chem Biol. 2024; 20(12):1650-1661.
PMID: 38649452
DOI: 10.1038/s41589-024-01611-7.
Understanding familial risk of pancreatic ductal adenocarcinoma.
Paranal R, Wood L, Klein A, Roberts N
Fam Cancer. 2024; 23(4):419-428.
PMID: 38609521
PMC: 11660179.
DOI: 10.1007/s10689-024-00383-2.
The one-carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation.
Marttila P, Bonagas N, Chalkiadaki C, Stigsdotter H, Schelzig K, Shen J
Mol Oncol. 2024; 18(9):2179-2195.
PMID: 38533616
PMC: 11467796.
DOI: 10.1002/1878-0261.13645.
Real-world data in patients with mutated breast cancer treated with poly (ADP-ribose) polymerase inhibitors.
Beas-Lozano E, Verduzco-Aguirre H, Gonzalez-Salazar R, Chavarri-Guerra Y
Ecancermedicalscience. 2024; 17:1633.
PMID: 38414963
PMC: 10898914.
DOI: 10.3332/ecancer.2023.1633.
Gender-Specific Genetic Predisposition to Breast Cancer: Genes and Beyond.
Valentini V, Bucalo A, Conti G, Celli L, Porzio V, Capalbo C
Cancers (Basel). 2024; 16(3).
PMID: 38339330
PMC: 10854694.
DOI: 10.3390/cancers16030579.
BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients.
Zhang Y, Wu H, Gan C, Rao H, Wang Q, Guo X
BMC Med Genomics. 2024; 17(1):3.
PMID: 38167124
PMC: 10763220.
DOI: 10.1186/s12920-023-01772-9.
Effects of Differing Underlying Assumptions in In Silico Models on Predictions of DNA Damage and Repair.
Warmenhoven J, Henthorn N, McNamara A, Ingram S, Merchant M, Kirkby K
Radiat Res. 2023; 200(6):509-522.
PMID: 38014593
PMC: 11590750.
DOI: 10.1667/RADE-21-00147.1.
Detection of Cancer-Associated Gene Mutations in Urinary Cell-Free DNA among Prostate Cancer Patients in South Africa.
Temilola D, Wium M, Paccez J, Salukazana A, Rotimi S, Otu H
Genes (Basel). 2023; 14(10).
PMID: 37895233
PMC: 10606409.
DOI: 10.3390/genes14101884.